Neuroprotective effects of the novel glutamate transporter inhibitor (-)-3-hydroxy-4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4-d]-isoxazole-4-carboxylic acid, which preferentially inhibits reverse transport (glutamate release) compared with glutamate reuptake

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Neuroprotective effects of the novel glutamate transporter inhibitor (-)-3-hydroxy-4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4-d]-isoxazole-4-carboxylic acid, which preferentially inhibits reverse transport (glutamate release) compared with glutamate reuptake. / Colleoni, Simona; Jensen, Anders Asbjørn; Landucci, Elisa; Fumagalli, Elena; Conti, Paola; Pinto, Andrea; De Amici, Marco; Pellegrini-Giampietro, Domenico E.; De Micheli, Carlo; Mennini, Tiziana; Gobbi, Marco.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 326, No. 2, 2008, p. 646-656.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Colleoni, S, Jensen, AA, Landucci, E, Fumagalli, E, Conti, P, Pinto, A, De Amici, M, Pellegrini-Giampietro, DE, De Micheli, C, Mennini, T & Gobbi, M 2008, 'Neuroprotective effects of the novel glutamate transporter inhibitor (-)-3-hydroxy-4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4-d]-isoxazole-4-carboxylic acid, which preferentially inhibits reverse transport (glutamate release) compared with glutamate reuptake', Journal of Pharmacology and Experimental Therapeutics, vol. 326, no. 2, pp. 646-656. https://doi.org/10.1124/jpet.107.135251

APA

Colleoni, S., Jensen, A. A., Landucci, E., Fumagalli, E., Conti, P., Pinto, A., De Amici, M., Pellegrini-Giampietro, D. E., De Micheli, C., Mennini, T., & Gobbi, M. (2008). Neuroprotective effects of the novel glutamate transporter inhibitor (-)-3-hydroxy-4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4-d]-isoxazole-4-carboxylic acid, which preferentially inhibits reverse transport (glutamate release) compared with glutamate reuptake. Journal of Pharmacology and Experimental Therapeutics, 326(2), 646-656. https://doi.org/10.1124/jpet.107.135251

Vancouver

Colleoni S, Jensen AA, Landucci E, Fumagalli E, Conti P, Pinto A et al. Neuroprotective effects of the novel glutamate transporter inhibitor (-)-3-hydroxy-4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4-d]-isoxazole-4-carboxylic acid, which preferentially inhibits reverse transport (glutamate release) compared with glutamate reuptake. Journal of Pharmacology and Experimental Therapeutics. 2008;326(2):646-656. https://doi.org/10.1124/jpet.107.135251

Author

Colleoni, Simona ; Jensen, Anders Asbjørn ; Landucci, Elisa ; Fumagalli, Elena ; Conti, Paola ; Pinto, Andrea ; De Amici, Marco ; Pellegrini-Giampietro, Domenico E. ; De Micheli, Carlo ; Mennini, Tiziana ; Gobbi, Marco. / Neuroprotective effects of the novel glutamate transporter inhibitor (-)-3-hydroxy-4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4-d]-isoxazole-4-carboxylic acid, which preferentially inhibits reverse transport (glutamate release) compared with glutamate reuptake. In: Journal of Pharmacology and Experimental Therapeutics. 2008 ; Vol. 326, No. 2. pp. 646-656.

Bibtex

@article{72733a7061fc11dd8d9f000ea68e967b,
title = "Neuroprotective effects of the novel glutamate transporter inhibitor (-)-3-hydroxy-4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4-d]-isoxazole-4-carboxylic acid, which preferentially inhibits reverse transport (glutamate release) compared with glutamate reuptake",
abstract = "(+/-)-3-Hydroxy-4,5,6,6a-tetrahydro-3aH-pyrrolo [3,4 -d]-isoxazole-4-carboxylic acid (HIP-A) and (+/-)-3-hydroxy-4,5,6, 6a-tetrahydro-3aH-pyrrolo[3,4-d]isoxazole-6-carboxylic acid (HIP-B) are selective inhibitors of excitatory amino acid transporters (EAATs), as potent as DL-threo-beta-benzyloxyaspartic acid (TBOA). We report here that the active isomers are (-)-HIP-A and (+)-HIP-B, being approximately 150- and 10-fold more potent than the corresponding enantiomers as inhibitors of [3H]aspartate uptake in rat brain synaptosomes and hEAAT1-3-expressing cells. Comparable IC(50) values were found on the three hEAAT subtypes. (-)-HIP-A maintained the remarkable property, previously reported with the racemates, of inhibiting synaptosomal glutamate-induced [3H]D-aspartate release (reverse transport) at concentrations significantly lower than those inhibiting [3H]L-glutamate uptake. New data suggest that the noncompetitive-like interaction described previously is probably the consequence of an insurmountable, long-lasting impairment of EAAT's function. Some minutes of preincubation are required to induce this impairment, the duration of preincubation having more effect on inhibition of glutamate-induced release than of glutamate uptake. In organotypic rat hippocampal slices and mixed mouse brain cortical cultures, TBOA, but not (-)-HIP-A, had toxic effects. Under ischemic conditions, a neuroprotective effect was found with 10 to 30 microM (-)-HIP-A, but not with 10 to 30 microM TBOA or 100 microM (-)-HIP-A. The effect of (-)-HIP-A suggests that, under ischemia, EAATs mediate both release (reverse transport) and uptake of glutamate. The neuroprotection with the lower (-)-HIP-A concentrations may indicate a selective inhibition of the reverse transport confirming the data obtained in synaptosomes. The selective interference with glutamate-induced glutamate release might offer a new strategy for neuroprotective action.",
keywords = "Animals, Biological Transport, Carboxylic Acids, Cell Line, Cell Survival, Culture Media, Dose-Response Relationship, Drug, Excitatory Amino Acid Transporter 1, Glutamic Acid, Humans, Male, Membrane Potentials, Molecular Structure, Neuroprotective Agents, Oxazoles, Rats, Rats, Inbred Strains, Stereoisomerism, Synaptosomes",
author = "Simona Colleoni and Jensen, {Anders Asbj{\o}rn} and Elisa Landucci and Elena Fumagalli and Paola Conti and Andrea Pinto and {De Amici}, Marco and Pellegrini-Giampietro, {Domenico E.} and {De Micheli}, Carlo and Tiziana Mennini and Marco Gobbi",
year = "2008",
doi = "10.1124/jpet.107.135251",
language = "English",
volume = "326",
pages = "646--656",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

RIS

TY - JOUR

T1 - Neuroprotective effects of the novel glutamate transporter inhibitor (-)-3-hydroxy-4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4-d]-isoxazole-4-carboxylic acid, which preferentially inhibits reverse transport (glutamate release) compared with glutamate reuptake

AU - Colleoni, Simona

AU - Jensen, Anders Asbjørn

AU - Landucci, Elisa

AU - Fumagalli, Elena

AU - Conti, Paola

AU - Pinto, Andrea

AU - De Amici, Marco

AU - Pellegrini-Giampietro, Domenico E.

AU - De Micheli, Carlo

AU - Mennini, Tiziana

AU - Gobbi, Marco

PY - 2008

Y1 - 2008

N2 - (+/-)-3-Hydroxy-4,5,6,6a-tetrahydro-3aH-pyrrolo [3,4 -d]-isoxazole-4-carboxylic acid (HIP-A) and (+/-)-3-hydroxy-4,5,6, 6a-tetrahydro-3aH-pyrrolo[3,4-d]isoxazole-6-carboxylic acid (HIP-B) are selective inhibitors of excitatory amino acid transporters (EAATs), as potent as DL-threo-beta-benzyloxyaspartic acid (TBOA). We report here that the active isomers are (-)-HIP-A and (+)-HIP-B, being approximately 150- and 10-fold more potent than the corresponding enantiomers as inhibitors of [3H]aspartate uptake in rat brain synaptosomes and hEAAT1-3-expressing cells. Comparable IC(50) values were found on the three hEAAT subtypes. (-)-HIP-A maintained the remarkable property, previously reported with the racemates, of inhibiting synaptosomal glutamate-induced [3H]D-aspartate release (reverse transport) at concentrations significantly lower than those inhibiting [3H]L-glutamate uptake. New data suggest that the noncompetitive-like interaction described previously is probably the consequence of an insurmountable, long-lasting impairment of EAAT's function. Some minutes of preincubation are required to induce this impairment, the duration of preincubation having more effect on inhibition of glutamate-induced release than of glutamate uptake. In organotypic rat hippocampal slices and mixed mouse brain cortical cultures, TBOA, but not (-)-HIP-A, had toxic effects. Under ischemic conditions, a neuroprotective effect was found with 10 to 30 microM (-)-HIP-A, but not with 10 to 30 microM TBOA or 100 microM (-)-HIP-A. The effect of (-)-HIP-A suggests that, under ischemia, EAATs mediate both release (reverse transport) and uptake of glutamate. The neuroprotection with the lower (-)-HIP-A concentrations may indicate a selective inhibition of the reverse transport confirming the data obtained in synaptosomes. The selective interference with glutamate-induced glutamate release might offer a new strategy for neuroprotective action.

AB - (+/-)-3-Hydroxy-4,5,6,6a-tetrahydro-3aH-pyrrolo [3,4 -d]-isoxazole-4-carboxylic acid (HIP-A) and (+/-)-3-hydroxy-4,5,6, 6a-tetrahydro-3aH-pyrrolo[3,4-d]isoxazole-6-carboxylic acid (HIP-B) are selective inhibitors of excitatory amino acid transporters (EAATs), as potent as DL-threo-beta-benzyloxyaspartic acid (TBOA). We report here that the active isomers are (-)-HIP-A and (+)-HIP-B, being approximately 150- and 10-fold more potent than the corresponding enantiomers as inhibitors of [3H]aspartate uptake in rat brain synaptosomes and hEAAT1-3-expressing cells. Comparable IC(50) values were found on the three hEAAT subtypes. (-)-HIP-A maintained the remarkable property, previously reported with the racemates, of inhibiting synaptosomal glutamate-induced [3H]D-aspartate release (reverse transport) at concentrations significantly lower than those inhibiting [3H]L-glutamate uptake. New data suggest that the noncompetitive-like interaction described previously is probably the consequence of an insurmountable, long-lasting impairment of EAAT's function. Some minutes of preincubation are required to induce this impairment, the duration of preincubation having more effect on inhibition of glutamate-induced release than of glutamate uptake. In organotypic rat hippocampal slices and mixed mouse brain cortical cultures, TBOA, but not (-)-HIP-A, had toxic effects. Under ischemic conditions, a neuroprotective effect was found with 10 to 30 microM (-)-HIP-A, but not with 10 to 30 microM TBOA or 100 microM (-)-HIP-A. The effect of (-)-HIP-A suggests that, under ischemia, EAATs mediate both release (reverse transport) and uptake of glutamate. The neuroprotection with the lower (-)-HIP-A concentrations may indicate a selective inhibition of the reverse transport confirming the data obtained in synaptosomes. The selective interference with glutamate-induced glutamate release might offer a new strategy for neuroprotective action.

KW - Animals

KW - Biological Transport

KW - Carboxylic Acids

KW - Cell Line

KW - Cell Survival

KW - Culture Media

KW - Dose-Response Relationship, Drug

KW - Excitatory Amino Acid Transporter 1

KW - Glutamic Acid

KW - Humans

KW - Male

KW - Membrane Potentials

KW - Molecular Structure

KW - Neuroprotective Agents

KW - Oxazoles

KW - Rats

KW - Rats, Inbred Strains

KW - Stereoisomerism

KW - Synaptosomes

U2 - 10.1124/jpet.107.135251

DO - 10.1124/jpet.107.135251

M3 - Journal article

C2 - 18451317

VL - 326

SP - 646

EP - 656

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -

ID: 5345193